Citigroup Initiates Coverage On Cytokinetics with Buy Rating, Announces Price Target of $99
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
Citigroup analyst Eric Joseph initiates coverage on Cytokinetics (NASDAQ:CYTK) with a Buy rating and announces Price Target of $99.
Citigroup analyst Eric Joseph initiates coverage on Cytokinetics (NASDAQ:CYTK) with a Buy rating and announces Price Target of $99.